Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses
- PMID: 32460166
- PMCID: PMC7251378
- DOI: 10.1016/j.ebiom.2020.102786
Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses
Abstract
Background: Pancreatic patient-derived organoids (PDOs) are a well-established model for studying pancreatic ductal adenocarcinoma (PDAC) carcinogenesis and are potential predictors of clinical responses to chemotherapy. Oncolytic virotherapy is envisioned as a novel treatment modality for pancreatic cancer, and candidate viruses are being tested in clinical trials. Here, we explore the feasibility of using PDOs as a screening platform for the oncolytic adenovirus (OA) response.
Methods: Organoids were established from healthy pancreas and PDAC tissues and assessed for infectivity, oncoselectivity, and patient-dependent sensitivity to OA. Antitumour effects were studied in vivo in organoid xenografts. Further evaluation of oncolytic responses was conducted in organoids derived from orthotopic models or metastastic tissues.
Findings: Oncolytic adenoviruses display good selectivity, with replication only in organoids derived from PDAC tumours. Furthermore, responses of PDOs to a set of OAs reveal individual differences in cytotoxicity as well as in synergism with standard chemotherapy. Adenoviral cytotoxicity in PDOs is predictive of antitumour efficacy in a subcutaneous xenograft setting. Organoids from orthotopic tumours and metastases in nude mice mirror the viral preference of PDOs, indicating that PDO sensitivity to OAs could be informative about responses in both primary tumours and metastatic foci.
Interpretation: Our data imply that pancreatic PDOs can serve as predictive tools for screening for sensitivity to OA.
Keywords: Oncolytic adenovirus (OA); Orthotopic tumours; Pancreatic ductal adenocarcinoma (PDAC); Patient-derived organoids (PDO).
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest SFB and HC declare that they hold a patent (WO2015/173425). All other authors declare no conflict of interest.
Figures






Comment in
-
Oncolytic virotherapy meets the human organoid technology for pancreatic cancers.EBioMedicine. 2020 Jul;57:102828. doi: 10.1016/j.ebiom.2020.102828. Epub 2020 Jun 20. EBioMedicine. 2020. PMID: 32574953 Free PMC article. No abstract available.
Similar articles
-
Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.Hum Gene Ther. 2020 Aug;31(15-16):891-903. doi: 10.1089/hum.2020.024. Epub 2020 Jun 30. Hum Gene Ther. 2020. PMID: 32475172
-
The use of pancreatic ductal adenocarcinoma 2D and 3D models to evaluate NDV infection, replication and induced cell death.Sci Rep. 2025 Jul 1;15(1):22178. doi: 10.1038/s41598-025-06023-8. Sci Rep. 2025. PMID: 40594584 Free PMC article.
-
Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids.STAR Protoc. 2021 Dec 11;2(4):101017. doi: 10.1016/j.xpro.2021.101017. eCollection 2021 Dec 17. STAR Protoc. 2021. PMID: 34950892 Free PMC article.
-
Advances in oncolytic adenovirus therapy for pancreatic cancer.Cancer Lett. 2018 Oct 10;434:56-69. doi: 10.1016/j.canlet.2018.07.006. Epub 2018 Jul 5. Cancer Lett. 2018. PMID: 29981812 Review.
-
Personalized Care for Pancreatic Cancer: Harnessing Patient-Derived Organoids.J Gastrointest Cancer. 2025 May 10;56(1):113. doi: 10.1007/s12029-025-01164-5. J Gastrointest Cancer. 2025. PMID: 40347361 Review.
Cited by
-
The LAMB3-EGFR signaling pathway mediates synergistic Anti-Cancer effects of berberine and emodin in Pancreatic cancer.Biochem Pharmacol. 2024 Oct;228:116509. doi: 10.1016/j.bcp.2024.116509. Epub 2024 Aug 28. Biochem Pharmacol. 2024. PMID: 39214450
-
Aronia Berry Extract Modulates MYD88/NF-kB/P-Glycoprotein Axis to Overcome Gemcitabine Resistance in Pancreatic Cancer.Pharmaceuticals (Basel). 2024 Jul 9;17(7):911. doi: 10.3390/ph17070911. Pharmaceuticals (Basel). 2024. PMID: 39065761 Free PMC article.
-
Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity.Immunology. 2021 Aug;163(4):389-398. doi: 10.1111/imm.13323. Epub 2021 Mar 28. Immunology. 2021. PMID: 33638871 Free PMC article. Review.
-
Immune organoid for cancer immunotherapy.Acta Pharm Sin B. 2025 Jul;15(7):3419-3435. doi: 10.1016/j.apsb.2025.04.031. Epub 2025 May 17. Acta Pharm Sin B. 2025. PMID: 40698131 Free PMC article. Review.
-
Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.Front Immunol. 2023 Dec 15;14:1308890. doi: 10.3389/fimmu.2023.1308890. eCollection 2023. Front Immunol. 2023. PMID: 38169820 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous